Show simple item record

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

dc.contributor.authorDöhner, Hartmut
dc.contributor.authorDiNardo, Courtney D
dc.contributor.authorWei, Andrew H
dc.contributor.authorLöwenberg, Bob
dc.contributor.authorAppelbaum, Frederick
dc.contributor.authorCraddock, Charles
dc.contributor.authorDombret, Hervé
dc.contributor.authorEbert, Benjamin L
dc.contributor.authorFenaux, Pierre
dc.contributor.authorGodley, Lucy A
dc.contributor.authorHasserjian, Robert P
dc.contributor.authorLarson, Richard A
dc.contributor.authorLevine, Ross L
dc.contributor.authorMiyazaki, Yasushi
dc.contributor.authorNiederwieser, Dietger
dc.contributor.authorOssenkoppele, Gert J
dc.contributor.authorRöllig, Christoph
dc.contributor.authorSierra, Jorge
dc.contributor.authorStein, Eytan M
dc.contributor.authorTallman, Martin S
dc.contributor.authorTien, Hwei-Fang
dc.contributor.authorWang, Jianxiang
dc.contributor.authorWierzbowska, Agnieszka
dc.date.accessioned2024-09-13T13:32:04Z
dc.date.available2024-09-13T13:32:04Z
dc.date.issued2024-08-12
dc.identifier.citationDöhner H, DiNardo CD, Wei AH, Löwenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Aug 12:blood.2024025409.en_US
dc.identifier.eissn1528-0020
dc.identifier.doi10.1182/blood.2024025409
dc.identifier.pmid39133932
dc.identifier.urihttp://hdl.handle.net/20.500.14200/5734
dc.description.abstractThe European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.sciencedirect.com/journal/blooden_US
dc.rightsCopyright © 2024 American Society of Hematology.
dc.subjectHaematologyen_US
dc.titleGenetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.en_US
dc.typeArticleen_US
dc.source.journaltitleBlooden_US
dc.source.countryUnited States
rioxxterms.versionNAen_US
dc.contributor.trustauthorCraddock, Charles
dc.contributor.departmentHaematologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.identifier.journalBlood
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record